Millie
your market intelligence analyst
Search Results
166 results
Your search is now limited to «Bristol-Myers Squibb» expert search.
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 8, 2011. The document announced the withdrawal of approval of 70 new drug applications (NDAs) and 97 abbreviated new drug applications from multiple applicants, effective July 8, 2011. The document contained the incorrect applicant information for NDA 018380. The correct applicant for NDA 018380 is Hospira, Inc. This document corrects that error.
pharmaphorum 08/19/2019 08:04
Celgene has scored a major regulatory win ahead of its proposed merger with Bristol-Myers Squibb, with the FDA backing its rare bone marrow cancer drug Inrebic.
More from pharmaphorum:
FiercePharmaManufacturing 08/14/2019 10:32
As pharma's earnings reports rolled out for the second quarter, market watchers pointed out a big positive: Growth rates, for many companies at least, were up. Way up. We've ranked the major players, from Regeneron's 20% sales hike to Teva's 8% drop.
More from FiercePharmaManufacturing:
ClinicalTrials.gov 08/13/2019 06:47
Condition : Healthy Participants Interventions : Drug: BMS-986165; Drug: Ritonavir Sponsor : Bristol-Myers Squibb Not yet recruiting.
More from ClinicalTrials.gov:
Seeking Alpha 08/08/2019 14:07
As the Celgene (CELG) acquisition heads towards closure, investors need to position themselves for owning shares in the new Bristol-Myers Squibb (BMY.
More from Seeking Alpha:
Benzinga 08/04/2019 08:01
Insider buying can be an encouraging signal for potential investors. Insiders were buying shares last week in the wake of earnings reports. Two big drugmakers saw sizable insider purchases in the past week. Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.
More from Benzinga:
FierceMedicalDevices 08/01/2019 12:45
The phase 1/2 uses Bristol-Myers Squibb’s approved immuno-oncology drugs Opdivo and Yervoy and has been enrolling patients since May.
More from FierceMedicalDevices:
PharmiWeb.com 07/29/2019 22:52
Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer. Companies plan indication-seeking trialWHIPPANY, N.J. & PRINCETON, N.J. & OSAKA, Japan--(BUSINESS WIRE)--Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. ("Ono") announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase in...
More from PharmiWeb.com:
Big News Network (UAE) 07/29/2019 15:37
Bristol-Myers Squibb intends to close the Celgene transaction at the earliest possible date, which it currently expects to be by the end of 2019 or the beginning of 2020.
More from Big News Network (UAE):
Business Wire 07/26/2019 06:59
PRINCETON, N.J.--(BUSINESS WIRE)-- #BMS --BMS Receives Positive CHMP Opinion Recommending Approval of Empliciti® Plus Pomalidomide and Low-Dose Dexamethasone...
More from Business Wire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications